Sign inJoin waitlistJoin the waitlist

William Wierda

Deputy Division Head for Clinical and Educational Affairs in Cancer Medicine · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present
Section of Chronic Lymphocytic Leukemia Division · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2026–2027
Hematology and Medical Oncology
University of California (San Diego) Medical Center
1996–1999
Internal Medicine
Duke University Hospital
1993–1996
Doctor of Medicine
1989–1993

Research

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Case report · Nature Reviews Clinical Oncology · 2018 · 1,951 citations
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
New England Journal of Medicine · 2013 · 1,914 citations
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
New England Journal of Medicine · 2020 · 1,804 citations

MK
Michael Keating
233 papers
SO
Susan O'Brien
222 papers
Hagop Kantarjian
194 papers
Alessandra Ferrajoli
192 papers
Jan Burger
137 papers
Nitin Jain
125 papers · 1 as a fellow
Guillermo Garcia-Manero
116 papers
Jorge Cortes
115 papers
ZE
Zeev Estrov
104 papers
Elias Jabbour
89 papers · 4 as a fellow
SF
Stefan Faderl
86 papers · 9 as a fellow
PT
Philip Thompson
67 papers · 37 as a resident

Grants

Chronic Lymphocytic Leukemia Research Consortium
National Cancer Institute · P01
Project lead · $3.1M · University of California, San Diego
2011–2018
Sapacitabine Therapy to Create Synthetic Lethality in DNA Repair-Deficient CLL
National Cancer Institute · R01
Contact PI · $954K · University of Tx Md Anderson Can Ctr
2012–2016
8-Chloro-Adenosine for Treatment of CLL (IND 68,229)
National Cancer Institute · R21
Contact PI · $611.6K · University of Tx Md Anderson Can Ctr
2009–2011

Clinical trials

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2020–2028
Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
Principal investigator · Withdrawn · Phase 1
M.D. Anderson Cancer Center
2019–2020
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Principal investigator · Terminated · Phase 1
M.D. Anderson Cancer Center
2017–2019
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
Principal investigator · Withdrawn · Phase 1
M.D. Anderson Cancer Center
2015–2017